Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • GPCR
    (2)
  • Others
    (2)
Filter
Search Result
Results for "

mouse gpr40

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | Inhibitors_Agonists
AM-4668
AM4668
T142021011531-27-3
AM-4668, a GPR40 (FFA1) agonist with oral availability, was optimized to reduce central nervous system (CNS) permeability, with a mouse brain plasma ratio of only 0.02, and significantly reduced blood glucose levels in human GPR40 knock-in mice.
  • Inquiry Price
6-8 weeks
Size
QTY
AMG 837 sodium salt
T14215865231-45-4
AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. IC50 value: 13 nM (EC50) [1] Target: GPR40 agonist AMG 837 displayed the expected t
  • Inquiry Price
1-2 weeks
Size
QTY
LY2922470
T158101423018-12-5
LY2922470 reduces glucose levels along with significant enhancements in insulin and GLP-1, which is the potential for the treatment of type 2 diabetes mellitus (T2DM). LY2922470 is an effective, selective, and orally available agonist of the G protein-cou
  • Inquiry Price
6-8 weeks
Size
QTY
ZLY032
T358162314465-67-1
ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)
  • Inquiry Price
6-8 weeks
Size
QTY